PharmaMar and Chugai Pharmaceutical Co., Ltd. have entered into a mutual early termination agreement for for the license, development and commercialization agreement for Zepsyre in Japan entered on December 22nd, 2016, with an effective date of termination in April 2019. Under the terms of this early termination agreement, PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and will receive a payment of €3,000,000 from Chugai in consideration for the early termination...